Twist Bioscience's 359% Squeeze Rests on an AI Story Yet to Appear in Revenue — $116 Is the Level That Ends It

Twist Bioscience's 359% Squeeze Rests on an AI Story Yet to Appear in Revenue — $116 Is the Level That Ends It

On August 19, Twist Bioscience (TWST) did something its earnings report couldn't explain. The stock jumped 22.6% to $142.39, adding roughly $1.7 billion of market value in a single session. The trigger was Anthropic's disclosure that its Claude models had designed protein binders that worked against 14 of 15 biological targets, and that Twist — alongside Adaptyv Bio — had independently synthesized and tested the designs. Twist was named an independent evaluator. It was not named a commercial partner, and the announcement disclosed no revenue for it. In the same hours, activist short seller Scorpion Capital said it is short the stock. TWST closed higher anyway, and it has kept climbing: as of this writing it trades at $145.59, a fresh 52-week high, up roughly 359% year to date.

Two forces made that reaction possible, and they are not the same force. The first is real earnings power. Twist sells synthetic DNA, "writing" genetic code on silicon chips, and the business has been compounding: in fiscal Q3 2026 revenue rose 23% year over year to $118.4 million, the 14th consecutive quarter of sequential growth; gross margin reached 52.8%; the DNA synthesis segment most exposed to AI-driven design grew 39%; and management raised full-year revenue guidance to $456–457 million while guiding to adjusted EBITDA breakeven in the fiscal fourth quarter. The quarter was a revenue beat — analysts modeled about $114.5 million — attached to an EPS miss, a $0.56 loss versus roughly $0.48 to $0.50 expected, on a GAAP quarterly loss of $35.1 million. The company still burns cash, with negative free cash flow of about $98 million over the trailing twelve months. None of that changed between August 4 and August 19. All of it was true at $100, right after the company priced an upsized $300 million offering at $96.

What changed on the 19th was narrative plus mechanics. Anthropic's research put Twist at the center of the AI-biology story, and the stock had the ammunition to run on it: about 23% of the freely traded float was short as of July 31, or 14.08 million shares — eleven-plus days to cover. A heavily shorted stock handed a fresh story moves differently than a fully covered one, because every forced buyer of borrowed shares feeds the rise. The broad market is trading near its own highs, a warm tape that tolerates momentum — which is exactly when a single name's vertical extension needs its own check, not a free pass.

That is the second force, and it is why no valuation model runs smooth here. At $145.59, Twist's market value is roughly $9.6 billion — about 21 times this year's guided revenue, against roughly 21% growth, for a business that is not yet profitable. The sell-side, which has been raising targets into the run, is still behind the price: Baird's latest is $115, Canaccord's is $120. Translate the multiple and you see what the market is asking the business to become. At a generous 10 times sales for a high-growth platform, a $9.6 billion company needs revenue near $960 million — more than double the current guide. At 6 times, nearer $1.6 billion, roughly triple. Choose your multiple; the price embeds a transformative outcome, not the guidance the company just issued.

That is not an accusation that the story is fake, and the bear case deserves a straight answer. Scorpion Capital attacked the company in 2022, called it a "ticking time bomb," drew Theranos comparisons, and Twist responded that the report was "highly misleading." The current version is a bet against the business's economics, not against whether AI biology matters. The way to test it is the revenue line, and the revenue line is improving. What remains unproven is the specific value of the August 19 role: an independent validation assignment that today carries zero disclosed revenue, priced by the market as a commercial franchise. That is the gap between the stock and the story, and it can be repriced without any earnings event at all.

Which is where the chart earns its keep, because it gives you the timing the fundamentals can't. TWST trades about 46% above its 50-day moving average, which sits near $100 — a stretched relationship that resolves by pullback, not by waiting. The August structure puts three reference points under the price. The mid-August consolidation topped out near $124.50–126.50; that is the ledge. Below it, the spike launched from around $116, the August 18 close. Below that sits the $99–100 floor: the August 4 post-offering low of $98.89, right at the 50-day.

The confirmation is straightforward. As long as TWST holds the roughly $125 ledge on any pullback, the breakout is intact; sustained trade above the ~$142 August 19 close keeps the leg extending into new highs — above $145.93 there is no overhead supply from the past year, only price discovery. The level that breaks the setup is a daily close back below $116–118, the shelf the spike launched from. That says the AI pop has round-tripped and the mechanics run in reverse: a stock that ran on short covering can hand the gains back the same way, and the gravity below is the $99–100 floor.

For a retail investor, the honest reading is that this is not the moment to chase, and it is not the moment to pronounce the story dead. "Don't chase" is the right posture at $145 partly because of what a reset would cost and partly because the setup hasn't proven itself: a vertical that runs on hope and covering doesn't become an investment until it builds a base. If AI biology is real — and the revenue line says it is — Twist's story will survive a base forming at lower prices, and that base is where the risk/reward turns in a buyer's favor. Watch the ledge at $125 and the shelf at $116. The market has been right that Twist sits at the center of synthetic biology's AI moment. What it has not been given is evidence that the last $45 of price rests on anything but hope and short covering. Let the levels test that gap for you. When the market charges more than the business can justify, the burden of proof belongs to the price — and prices revert when the proof doesn't arrive on time.